Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Cirrhosis and cancers of the upper digestive tract, colorectal and ENT share common risk factors. Liver cirrhosis can change the elimination of cancer drugs.
Precise data on management and outcome of patients with liver cirrhosis undergoing chemotherapy are lacking. Most patients have been excluded from clinical trials evaluating conventional therapies.
The study of tolerance, side effects, and outcome in patients with cirrhosis could help improve chemotherapy management for better tolerance and efficacy.
The main objective is to estimate the frequency of liver cirrhosis among patients evaluated in CPR for ENT, upper digestive or colorectal cancer.
Secondary objective includes the evaluation ofthe impact of cirrhosis on the management of chemotherapy by comparing cirrhotic patients' outcomes with a control group of matched non-cirrhotic patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
7 participants in 2 patient groups
Loading...
Central trial contact
Massih Ningarhari, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal